CN105919969A - 盐酸普鲁卡因微囊及其制备方法 - Google Patents
盐酸普鲁卡因微囊及其制备方法 Download PDFInfo
- Publication number
- CN105919969A CN105919969A CN201610359251.8A CN201610359251A CN105919969A CN 105919969 A CN105919969 A CN 105919969A CN 201610359251 A CN201610359251 A CN 201610359251A CN 105919969 A CN105919969 A CN 105919969A
- Authority
- CN
- China
- Prior art keywords
- procaine hydrochloride
- capsule
- micro
- capsule material
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 title claims abstract description 110
- 229960001309 procaine hydrochloride Drugs 0.000 title claims abstract description 110
- 239000003094 microcapsule Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 50
- 239000002775 capsule Substances 0.000 claims abstract description 49
- 239000000843 powder Substances 0.000 claims abstract description 33
- 239000004925 Acrylic resin Substances 0.000 claims abstract description 6
- 229920000178 Acrylic resin Polymers 0.000 claims abstract description 6
- 235000010489 acacia gum Nutrition 0.000 claims abstract description 6
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims abstract description 6
- 108010010803 Gelatin Proteins 0.000 claims abstract description 5
- 229920000159 gelatin Polymers 0.000 claims abstract description 5
- 239000008273 gelatin Substances 0.000 claims abstract description 5
- 235000019322 gelatine Nutrition 0.000 claims abstract description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229940072056 alginate Drugs 0.000 claims abstract description 4
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 4
- 229920000615 alginic acid Polymers 0.000 claims abstract description 4
- 239000001913 cellulose Substances 0.000 claims abstract description 3
- 229920002678 cellulose Polymers 0.000 claims abstract description 3
- 239000000725 suspension Substances 0.000 claims description 18
- 239000011265 semifinished product Substances 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 21
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 9
- 239000001856 Ethyl cellulose Substances 0.000 description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 8
- 235000019325 ethyl cellulose Nutrition 0.000 description 8
- 229920001249 ethyl cellulose Polymers 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 229960003920 cocaine Drugs 0.000 description 4
- 239000003589 local anesthetic agent Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000010413 sodium alginate Nutrition 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610359251.8A CN105919969B (zh) | 2016-05-27 | 2016-05-27 | 盐酸普鲁卡因微囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610359251.8A CN105919969B (zh) | 2016-05-27 | 2016-05-27 | 盐酸普鲁卡因微囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105919969A true CN105919969A (zh) | 2016-09-07 |
CN105919969B CN105919969B (zh) | 2019-01-08 |
Family
ID=56842349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610359251.8A Active CN105919969B (zh) | 2016-05-27 | 2016-05-27 | 盐酸普鲁卡因微囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105919969B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108309956A (zh) * | 2018-02-06 | 2018-07-24 | 重庆医科大学附属永川医院 | 一种用于局部麻醉的纤维膜及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102058523A (zh) * | 2009-11-13 | 2011-05-18 | 天津金世制药有限公司 | 一种普鲁卡因注射液 |
CN102366399A (zh) * | 2011-09-28 | 2012-03-07 | 河南辅仁怀庆堂制药有限公司 | 盐酸普鲁卡因注射液及其生产工艺 |
CN105147638A (zh) * | 2015-10-30 | 2015-12-16 | 成都通德药业有限公司 | 一种复方盐酸普鲁卡因胶囊的生产方法 |
-
2016
- 2016-05-27 CN CN201610359251.8A patent/CN105919969B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102058523A (zh) * | 2009-11-13 | 2011-05-18 | 天津金世制药有限公司 | 一种普鲁卡因注射液 |
CN102366399A (zh) * | 2011-09-28 | 2012-03-07 | 河南辅仁怀庆堂制药有限公司 | 盐酸普鲁卡因注射液及其生产工艺 |
CN105147638A (zh) * | 2015-10-30 | 2015-12-16 | 成都通德药业有限公司 | 一种复方盐酸普鲁卡因胶囊的生产方法 |
Non-Patent Citations (2)
Title |
---|
毕殿洲: "《药剂学》", 28 February 2003 * |
祁学忠等: "盐酸氯普鲁卡因三种剂型的比较", 《科技情报开发与经济》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108309956A (zh) * | 2018-02-06 | 2018-07-24 | 重庆医科大学附属永川医院 | 一种用于局部麻醉的纤维膜及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105919969B (zh) | 2019-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4365107B2 (ja) | 医薬組成物 | |
JP2021193091A (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
KR101865194B1 (ko) | 아라키돈산 유사체 및 이를 사용한 진통제 치료 방법 | |
CN107789340A (zh) | 一种穿心莲雾化吸入用溶液制剂及其制备方法 | |
MXPA04008720A (es) | Suspension oral de sabor agradable y metodo. | |
CN111529534A (zh) | 用于治疗肥胖症的化合物和其使用方法 | |
JP2014031367A (ja) | 交感神経活発化剤 | |
CN102481287B (zh) | 含维生素c或其衍生物的替莫唑胺药物组合物及其制备方法 | |
CN105919969A (zh) | 盐酸普鲁卡因微囊及其制备方法 | |
CN101317846B (zh) | 一种用于戒毒、镇痛的河豚毒素制剂 | |
CN106619565B (zh) | 精氨酸制剂及其制备方法和应用 | |
EA007010B1 (ru) | Энтеральные соли кетокислот и аминокислот | |
WO2002030417A1 (fr) | Suspensions medicamenteuses contenant des acides amines ramifies | |
WO2023005875A1 (en) | Photoactivatable prodrug nanoparticles for combined anti-angiogenesis and photodynamic therapy | |
KR101513848B1 (ko) | 몬테루카스트 및 그의 약제학적으로 허용 가능한 염을 포함하는 안정성이 개선된 시럽 제제 및 그의 제조 방법 | |
CN110339169A (zh) | 包覆维生素d和维生素k的纳米囊泡制剂及其应用 | |
CN105163732A (zh) | 用于治疗眼科疾病和病症的方法 | |
JP7312340B2 (ja) | 水素を含む加齢黄斑変性治療用組成物 | |
JP6163169B2 (ja) | コカイン中毒者の処置におけるモダフィニルの使用 | |
CN110237033A (zh) | 一种2,4二硝基苯酚注射液及其制备方法和用途 | |
CN106806418A (zh) | 一种双黄连雾化吸入用溶液制剂及其制备方法 | |
KR101458670B1 (ko) | 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법 | |
CN109200051A (zh) | 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途 | |
CN113577059B (zh) | 一种用于小儿哮喘的活性药物 | |
CN108904501B (zh) | 一种化合物在治疗或预防高原病中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171128 Address after: 450000 Henan province air port area of the new township of the north side of the road on the north side of the eight thousand Applicant after: ZHENGZHOU BARY ANIMAL PHARMACEUTICAL Co.,Ltd. Address before: 450001 Zhengzhou City, Henan Province, Zhengzhou high new district, the east of the East, the north of the Holly Street, 9 houses 15 floors 1503 room Applicant before: ZHENGZHOU RUIQI BIOTECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240613 Address after: Room D-1-2501, 2510, Incubator, No. 319 Xiangjiang Road, High tech Zone, Shijiazhuang City, Hebei Province, 050000 Patentee after: Hebei Puyou Biotechnology Co.,Ltd. Country or region after: China Address before: 450000 North side of Xinchun Road, Baqian Township, Hangang District, Zhengzhou City, Henan Province Patentee before: ZHENGZHOU BARY ANIMAL PHARMACEUTICAL Co.,Ltd. Country or region before: China |